Keros Therapeutics Inc(KROS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.7 | Insider Own | 8.45% | Shs Outstand | 19.8M | Perf Week | 3.85% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | -12.61% | Insider Trans | -0.84% | Shs Float | 18.1M | Perf Month | 3.75% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.94 | Inst Own | 92.13% | Short Float | 6.26% | Perf Quarter | 13.6% |
| Income | -0.08B | P/S | 15.34 | EPS this Y | -340.77% | Inst Trans | - | Short Ratio | 6.07 | Perf Half Y | 4.59% |
| Sales | 0.02B | P/B | 0.88 | EPS next 5Y | - | ROA | -15.92% | Short Interest | 1.14M | Perf YTD | -42.98% |
| Book/sh | 13.23 | P/C | 0.89 | EPS past 3/5Y | - | ROE | -17.16% | 52W High | -48.51% ($22.55) | Perf Year | -23.52% |
| Cash/sh | 12.99 | P/FCF | - | Sales past 3/5Y | - | ROIC | -30.19% | 52W Low | 19.81% ($9.69) | Perf 3Y | -58.03% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1143.58% | Gross Margin | 89.34% | Volatility(W/M) | 3.65% 4.39% | Perf 5Y | -72.5% |
| Dividend TTM | - | EV/Sales | -0.78 | Sales Y/Y TTM | -93.55% | Oper. Margin | -675.27% | ATR (14) | 0.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 21.96 | EPS Q/Q | -91.85% | Profit Margin | -553.88% | RSI (14) | 55.58 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.96 | Sales Q/Q | -100% | SMA20 | 2.64% ($11.31) | Beta | 1.13 | Target Price | $19.83 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/3 | SMA50 | 3.06% ($11.27) | Rel Volume | 0.98 | Prev Close | $11.43 |
| Employees | 78 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | -8.21% -100% | SMA200 | -4.42% ($12.15) | Avg Volume(3M) | 0.19M | Price | $11.61 |
| IPO | 2020/4/8 | Option/Short | Yes/Yes | Trades | 2567 | Volume | 182,773 | Change | 1.62% |
🧬 Keros Therapeutics (ticker: KROS) is a US-based, clinical-stage biotech company developing novel therapeutics that modulate signaling of the TGF-beta protein superfamily. The company's core focus is treating anemia in blood disorders, with lead candidates targeting anemia associated with myelodysplastic syndromes and myelofibrosis, while also expanding its pipeline into adjacent areas such as muscle disorders.
Over the past 1 year, on the lower side
49% below its 1-year high.
Traded about as much as usual. That is 98% of its average volume.
KROS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -340.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,534. Peers typically go for $1,034. Compared with its own 1-year average, it is 77% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -72.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 92.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #288 of 594 in the industry
Based on market cap of $230M.
KROS#288 Keros Therapeutics Inc $230M PER - 
CAMP#289 CAMP4 Therapeutics Corp $229M PER - 
EVMN#290 Evommune Inc $229M PER - 
IKT#291 Inhibikase Therapeutics Inc $226M PER - 
ELDN#292 Eledon Pharmaceuticals Inc $224M PER - 
FAQ
What kind of company is KROS?
KROS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KROS?
The market cap of KROS is approximately $230M, ranking 3,914 within its sector.
What is the 52-week high and low for KROS?
KROS has recorded a 52-week high of $22.55 and a low of $9.69.
